Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
Apabetalone
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/18/2021
hu33
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/25/2022
FN3B
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
mAB 1-68
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
Vistusertib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/25/2021
BD-368-2
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/14/2020
Molnupiravir
Emergency use authorization Experimental Antiviral Jun/23/2022
Ginkgo biloba leaves extract
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/22/2021
Phloretin
Potential treatment - theoretical effect Natural product Antiviral Mar/11/2021
mAb 2-51
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
L-Carnitine
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/14/2021
Mefuparib hydrochloride
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/26/2021
CA521FALA
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/23/2021
hACE21−740-Fc
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/11/2021
Rosmarinic acid
Potential treatment - theoretical effect Natural product Antiviral Mar/11/2021
Ginkgolic acid C17:1
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/22/2021
Indole-3-carbinol
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/24/2021
Tipiracil 
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/09/2021
AT-511
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/08/2021
P2C-1A3
Potential treatment - pre-clinical evidence Experimental Antiviral May/26/2020